Skip to main content

Table 1 Pathogens associated with infections caused in the study population

From: Pharmacokinetics of tigecycline in critically ill patients with liver failure defined by maximal liver function capacity test (LiMAx)

  Total (n = 33) Group A (n = 5) Group B (n = 21) Group C (n = 7) MIC breakpoints (mg/L)
Microbiological isolate, n (%)
 Enterococcus avium 1 (3) 0 1 (4.8) 0 0.12
 Enterococcus faecalis 3 (9.1) 2 (40) 1 (4.8) 0 0.12
 Enterococcus faecium 11 (33.3) 4 (80) 7 (33.3) 0 0.12
 Escherichia coli 4 (12.1) 2 (40) 2 (9.5) 0 0.5
 MRSA 1 (3) 0 0 1 (14.3) 0.25
 Staphylococcus epidermidis 2 (6.1) 0 3 (14.3) 1 (14.3) 0.12
 VRE 9 (27.3) 2 (40) 3 (14.3) 4 (57.1) 0.12
 ESBL 10 (30.3) 3 (60) 4 (19) 3 (42.9) 0.5
  1. MRSA: methicillin-resistant Staphylococcus aureus; VRE: vancomycin-resistant Enterococci; ESBL: extended betalactamase producing Gram-negative bacteria; MIC: minimum inhibitory concentration